ArticleAmerican journal of physiology. Lung cellular and molecular physiology2024
Longitudinal importance of the soluble receptor for advanced glycation end-products in nonintubated hospitalized patients with COVID-19 pneumonia.
Katherine D Wick, Lianne Siegel, Cathryn Oldmixon, Jens D Lundgren, B Taylor Thompson, Chayse Jones, Carolyn Leroux, Michael A Matthay, ACTIV-3/TICO Study Group
Abstract read
In one paragraphArticle in American journal of physiology. Lung cellular and molecular physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Katherine D WickCardiovascular Research Institute, University of California, San Francisco, California, United States.ORCID 0000-0001-9070-5490 Lianne SiegelDivision of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, Minnesota, United States.
Cathryn OldmixonBiostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, United States.
Jens D LundgrenCHIP (Centre of Excellence for Health, Immunity and Infections), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
B Taylor ThompsonDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States.
Chayse JonesCardiovascular Research Institute, University of California, San Francisco, California, United States.
Carolyn LerouxCardiovascular Research Institute, University of California, San Francisco, California, United States.
Michael A MatthayCardiovascular Research Institute, University of California, San Francisco, California, United States.ORCID 0000-0003-3039-8155 ACTIV-3/TICO Study Group
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating CenterOT2HL156812 · NHLBI · RESEARCH TRIANGLE INSTITUTE · PI NOLEN, TRACY L, THOMAS, SONIA M · 2020 to 2024
$1270.7MPrecision Medicine in the Acute Respiratory Distress SyndromeR35HL140026 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CALFEE, CAROLYN · 2018 to 2024
$6.8MModeling chikungunya virus infection in a vascularized bone modelR21AI140026 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DUAN, BIN, REID, PATRICK M · 2018 to 2019
$419kHHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R35HL140026HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R35HL140026Leidos (Leidos Holdings, Inc.)NCI NIH HHS 75N91019D00024NHLBI NIH HHS OT2 HL156812NHLBI NIH HHS R35 HL140026
6 · The paper itselfAbstract
The soluble receptor for advanced glycation end-products (sRAGE) is a marker of alveolar type I cell injury associated with outcomes in COVID-19 pneumonia. How plasma sRAGE changes over time and whether it remains associated with long-term clinical outcomes beyond a single measurement in COVID-19 have not been well studied. We studied two cohorts in randomized clinical trials of monoclonal antibody treatment for COVID-19 (bamlanivimab and tixagevimab/cilgavimab). We first studied the association between baseline plasma sRAGE and 90-day clinical outcomes, which had been previously demonstrated in the bamlanivimab cohort, among hospitalized patients with COVID-19 supported with high-flow nasal oxygen (HFNO) or noninvasive ventilation (NIV) in the tixagevimab/cilgavimab study. Next, we investigated the relationship between
Indexed as
COVID-19HospitalizationReceptor for Advanced Glycation End ProductsSARS-CoV-2AgedAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingBiomarkersCOVID-19 Drug TreatmentFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingbamlanivimabBiomarkersReceptor for Advanced Glycation End Productsalveolar epitheliumbiomarkerCOVID-19pneumoniaRAGE
Identifiers
PMID39076084
PMCPMC11563646
What Socratic holds
Textmetadata
Read underepoch 390